Pharmacy PrEP Education
A “How To” Series Spanning Policy to Practice
PrEP Pharmacy Monograph and State-Supplements
Providing PEP/PrEP in the Pharmacy Setting: A Comprehensive User Guide
Are you seeking specific insights and suggestions as you prepare to implement postexposure prophylaxis (PEP) and preexposure prophylaxis (PrEP) in your pharmacy practice? This activity qualifies participants for 2.0 CPE credits to fulfill State Board of Pharmacy training requirements
Calling all pharmacists from: Nevada, Oregon, and Virginia!
Your Board of Pharmacy has recently expanded your scope of practice to include prescribing and dispensing of PrEP and PEP. Learn the details specific to your state with these short primers:
- Providing PrEP in the Pharmacy Setting: Nevada Edition
- Providing PrEP in the Pharmacy Setting: Oregon Edition
- Providing PrEP in the Pharmacy Setting: Virginia Edition
CLINICAL PRACTICE GUIDELINES
Preexposure prophylaxis for the prevention of HIV infection in the United States—2021 update. A clinical practice guideline.
US Public Health Service. Centers for Disease Control and Prevention; 2021.
Sexually transmitted infections treatment guidelines, 2021.
Centers for Disease Control and Prevention. Last reviewed July 2021.
Updated guidelines for antiretroviral postexposure prophylaxis after sexual, injection drug use, or other nonoccupational exposure to HIV—United States, 2016.
CDC Stacks. Centers for Disease Control and Prevention; last updated May 2018.
The Fenway Guide to Lesbian, Gay, Bisexual, and Transgender Health.
Makadon HJ, et al, American College of Physicians (ACP), eds. 2nd ed. Boston, MA: Fenway Health; 2015.
Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society—USA Panel.
Saag MS, et al. JAMA. 2020;324(16):1651-1669.
ASHP [American Society of Health-System Pharmacists] guidelines on pharmacist involvement in HIV care.
Schafer JJ, et al. Am J Health Syst Pharm. 2016;73(7):468-494.
Guidelines for the use of antiretroviral agents in adults and adolescents living with HIV.
US Department of Health and Human Services; last updated January 2022.
PROFESSIONAL ORGANIZATIONS & RESOURCES
American Academy of HIV Medicine.
AIDS Education & Training Center (AETC) Program: National Coordinating Resource Center
Provides consultation, training, and resources nationwide.
A guide to taking a sexual history.
Centers for Disease Control and Prevention. 2022.
Basic statistics.
Centers for Disease Control and Prevention; updated April 2022.
HIV testing.
Centers for Disease Control and Prevention; June 2022.
HIV testing in retail pharmacies (training for pharmacists and pharmacy staff).
Centers for Disease Control and Prevention; Updated 2022.
Taking Routine Histories of Sexual Health: A System-Wide Approach for Health Centers.
National LGBTQIA+ Health Education Center. 2016.
Ending the HIV epidemic: Ready, Set, PrEP!
US Department of Health and Human Services.
Please PrEP Me
Both professional and patient resources as well as a state-by-state list of PrEP resources in all 50 states.
Preexposure prophylaxis for the prevention of HIV infection in the United States—2021 update. Clinical providers’ supplement.
US Public Health Service. Centers for Disease Control and Prevention; 2021.
National Clinician Consultation Center.
University of California, San Francisco; 2020.
HIV drug interactions.
University of Liverpool (website); updated July 2022.
Sexual History Taking Toolkit.
TargetHIV. 2022.
PATIENT RESOURCES
HIV basics.
Centers for Disease Control and Prevention; April 2021.
Prevention for women. Resources on HIV prevention for U.S. women.
HIVE online; 2019.
HIV resources.
National Institutes of Health; September 2020.
Positively Aware.
Positively Aware, created by TPAN (Test Positive Aware Network), is a source of HIV-treatment news for consumers, as well as an educational tool for HIV caregivers. The site features PrEP resources, including videos for men who have sex with men and transgender people.
UCSF transgender care.
University of California, San Francisco; 2019.
Suggested Readings
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Baeten JM, et al. N Engl J Med. 2012;367(5):399-410.
Stigma, medical mistrust, and perceived racism may affect PrEP awareness and uptake in black compared to white gay and bisexual men in Jackson, Mississippi and Boston, Massachusetts.
Cahill S, et al. AIDS Care. 2017;29(11):1351-1358.
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Choopanya K, et al. Lancet. 2013;381(9883):2083-2090.
Assessing the efficacy and feasibility of a retail pharmacy-based HIV testing program.
Collins BC, et al. 24th Conference on Retroviruses and Opportunistic Infections (CROI) 2017; February 13-17, 2017; Seattle, WA. Abstract 962.
Community pharmacy delivered PrEP to STOP HIV transmission: an opportunity NOT to miss!
Lopez MI, et al. J Am Pharm Assoc (2003). 2020;60(4):e18-e24.
Why don't patients take their drugs? The role of communication, context and culture in patient adherence and the work of the pharmacist in HIV/AIDS.
Penn C, et al. Patient Educ Couns. 2011;83(3):310-318.
4 findings from a successful HIV PrEP program.
Ross M. Pharm Times. 2016-01-07;15:30:00.
Truvada: emtricitabine/tenofovir disoproxil.
European Medicines Agency (EMA). 2021.
Emtricitabine/tenofovir alafenamide.
HIV.gov. Drug database.
Emtricitabine/tenofovir disoproxil fumarate.
HIV.gov. Drug database.
Cabotegravir.
HIV.gov. Drug database.
Being PrEPared—preexposure prophylaxis and HIV disparities.
Goldstein RH, et al. N Engl J Med. 2018;379(14):1293-1295.
Lifetime risk of a diagnosis of HIV infection in the United States.
Hess KL, et al. Ann Epidemiol. 2017;27(4):238-243.
Cabotegravir for HIV prevention in cisgender men and transgender women.
Landovitz RJ, et al. N Engl J Med. 2021;385(7):595-608.
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Mayer KH, et al. Lancet. 2020;396(10246):239-254.
Implementation of a community pharmacy-based pre-exposure prophylaxis service: a novel model for pre-exposure prophylaxis care.
Tung EL, et al. Sex Health. 2018;15(6):556-561.
HIV testing in community pharmacies and retail clinics: a model to expand access to screening for HIV infection.
Weidle PJ, et al. J Am Pharm Assoc. 2014; 54(5):486-492.
Pharmacy PrEP Education: A “How To” Series Spanning Policy to Practice
Pharmacy PrEP Education: A “How-to” Series Spanning Policy to Practice
Pharmacy PrEP Education: A “How-to” Series Spanning Policy to Practice
Pharmacy PrEP Education: A “How-to” Series Spanning Policy to Practice
Pharmacy PrEP Education: A “How-to” Series Spanning Policy to Practice
Relevant Resources
Overcoming Pain and Gastrointestinal Distress to Improve Patient Outcomes
Evidence-Based Strategies for Improved Patient Outcomes
Proactive Diagnosis and Targeted Management
Differential Diagnosis and Comprehensive Management Strategies
Optimizing Maintenance Therapy Across Healthcare Settings
Evolving Strategies for Diagnosis and Long-Term Management
Consensus and Controversies for Responsible Opioid Prescribing
Best Practices in Combination Therapy
Evolving Approaches to Insulin Based Therapy
Improving Outcomes for Patients with COPD
New Strategies for Insulin Replacement Therapy
Clinical Updates in LDL-C Management
Improving Comprehensive Patient Care
Identifying Patients and Tailoring Therapy
Collaborative Approaches to Guideline-Concordant Patient Care
New Strategies for Individualizing Long-term Care
A Focus on Patients With Opioid-Induced Constipation
Consensus and Controversies Across the Spectrum of Patient Presentations
Evolving Treatment Algorithms and Expert Perspectives on Biosimilars
Evolving Best Practices to Optimize Outcomes
The PCPs Role in Preventing HIV
The PCP’s Role in Timely Recognition and Referral
What Do You Know About PrEP?
Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care
What Do You Know About PrEP?
Got it? Treat it!
The Critical Role of the Community Pharmacist
Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.
Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box
Differential Diagnosis, Multidisciplinary Management, and Patient Engagement
Key Issues Impacting OB/GYN Practice
Hot Topics in HBV, HCV, and NASH
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Why It Matters in OB/GYN Practice Today
Improving Patient Outcomes Through Shared Clinical Decision Making
A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities
How the Pharmacist Can Make a Difference
Mechanistic Insights and Evolving Treatment Options
HIV Can Be Prevented— Are You Doing Your Part?
Rapid Start ART — A New Model for HIV Care
Clinical Resource Center
Understanding the Growing Syndemic — Opioids, HCV, and HIV
A Case-Based Conversation on Managing Asthma and Chronic Rhinosinusitis With Nasal Polyposis
The Clinical and Utilization Benefits of Exacerbation Prevention
A PrEP Primer
A Foundation for Managed Care
Cardiovascular and Renal Outcomes With SGLT2 Inhibitors
Best Practices for Primary Care
New Paths to Chronic Pain Management
The PCP’s Role in HCV Elimination
What the Pharmacist Needs to Know about PrEP
The Rapid ART Standard of Care: From Evidence to Healthcare Equity
Unlocking Novel Paths to Patient Care
Maximizing Your Role to Impact Patient Outcomes
Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV
Benefits, Barriers, & Best Practices in an Advancing Field
Practical Solutions Across the Spectrum of Care
Informing the Future of NASH Diagnosis and Assessment
A PEP/PrEP Training Guide for Pharmacists
The Increasing Role of JAK Inhibitors
Preventing COPD Exacerbations to Improve Outcomes
A Critical Step Toward HCV Elimination
Considering the Patient, the Provider, and the Science
A Multidisciplinary Online Mini-Curriculum
A Whole Patient Case Series
Debates and Discussions about Monoclonal Antibody Therapies
An Update on Monoclonal Antibody Therapies
Getting on the Fast Track to Identify AxSpA
Establishing Clinical Readiness Through Mentored Learning
Interdisciplinary Strategies for Adult and Pediatric Patients
Interdisciplinary Management of Eosinophilic Esophagitis and Hereditary Angioedema
Reducing LDL-C and a Lifetime of Cardiovascular Risk
Updates, Clinical Scenarios, and Future Directions
A Multidisciplinary Look at Early Diagnosis and Management
Recent Developments in Anti-SARS-CoV-2 Monoclonal Antibodies for Treatment
Best Practices for Diagnosis and Management
An Update on Best Practices
New Avenues to Pre-Exposure Prophylaxis
Are You Aware of New Blood-Based Multi-Cancer Screening Tools
An Updated Clinician’s Guide to Assessment and Management
What the Pharmacist Needs to Know
A Look at the Changing HIV Playing Field
Test Your Mastery!
Building Bridges to Reach People who Inject Drugs with the Goal of Employing PrEP for HIV Prevention
Strengthening Your Knowledge of Blood-Based Screening Tools
Bringing HIV Prevention to a New Level
Optimizing HIV Prevention in Primary Care
What You Need to Know About New Blood-Based Screening Tools
Monoclonal Antibodies for the Prevention and Treatment of COVID-19
Exploring New Treatment Avenues in Nonadvanced Systemic Mastocytosis
Practical Updates on the 2023 GOLD Guidelines
A Phone-a-Friend CME Series – Volume 2
Best Practices for Screening, Diagnosis, and Management
Incorporating New Data and Updated Guidelines Into Daily Practice
Focus on Psoriasis
Capitalizing on BCMA-Directed Therapies
From the Airway Epithelium to Improved Patient Outcomes
Exercising Best Practices for Hospitalized Patients
Accelerating Diagnosis and Treatment
